medicine (Photo credit: taiyofj)
Judging by some of the heavy action in the world of biotechnology, one could easily conclude that the industry is going to the dogs. Or cats, maybe.
There are start-ups named Nexvet and VetDC, CanFel Therapeutics (as in canine and feline), and even Fetch Pharma.
It’s a new example of pack behavior: Entrepreneurs with pedigrees from companies like Genentech and Amgen are now turning their attention to pets. They hope to develop innovative drugs for dogs and cats like those that have revolutionized the treatment of diseases like cancer and arthritis in people.
“We’ve been drugging ourselves for a long time and more recently we’ve been drugging our kids,” said Oleg Nodelman, an investor in and director of Kindred Biosciences, one of the new companies. “Why shouldn’t our pets have access to medicine?”
They do already, of course. Many of the big pharmaceutical companies have long had veterinary drug divisions. Eli Lilly’s animal division, Elanco, for instance, sells the company’s Prozac antidepressant under the name Reconcile to treat canine separation anxiety.
But the new entrepreneurs say they will be more nimble and do what the big companies are not doing, just as the early human medicine biotech companies did.
The big companies focus more on livestock — edible animals as opposed to petable ones, said Steven St. Peter, chief executive of Aratana Therapeutics, a pet biotech company. Their offerings for pets are mainly vaccines and treatments for fleas, ticks and worms.
The new companies hope instead to treat diseases like cancer and arthritis. Many are trying to develop monoclonal antibodies, which are proteins made in living cells. Such antibodies, like Humira for rheumatoid arthritis and Herceptin for breast cancer, are huge sellers in human medicine but have had almost no role so far in animal health.
Read more . . .
The Latest on: Biotech Drugs for Pets
via Google News
The Latest on: Biotech Drugs for Pets
- As push to disrupt PD-(L)1 pricing heats up, Checkpoint trumpets a pivotal successon January 25, 2022 at 7:19 am
The crowded PD-(L)1 market has proven lucrative for biopharma’s earliest entrants like Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, but newer drugs have struggled to pry away market share. One ...
- Fierce JPM Week: Confidence is high for Eli Lilly CEO Ricks in showdown with Biogen's Aduhelmon January 20, 2022 at 5:00 am
Eli Lilly is so serious about becoming the leader in Alzheimer’s disease with donanemab that the Indianapolis Big Pharma challenged competitor Biogen to a head-to-head trial for their two therapies ...
- XtalPi Partners with Excelra for GOSTAR to Enhance its Intelligent Digital Drug Discovery and Development platformon January 19, 2022 at 1:06 am
Excelra, a leading global Data & Analytics organization, today announced the partnership for its Global Online Structure Activity Relationship Database (GOSTAR) with XtalPi Inc., an AI-based ...
- Nutra Pharma Letter to Shareholderson January 18, 2022 at 9:47 am
As we have persevered through another pandemic year of 2021; we are looking forward to a much brighter 2022,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corpor ...
- Martin Shkreli receives lifetime industry ban, forced to return almost $65M in profits after anticompetitive schemeon January 18, 2022 at 6:30 am
Martin Shkreli will have to find a new nickname. A federal judge banned the former biotech CEO and “Pharma Bro” from the drug industry on Friday, ordering him to pay nearly $65 million in illicit ...
- BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001on January 18, 2022 at 5:02 am
No significant difference was observed in bioavailability and total exposure of BETR-001 in PK profile of fed versus fasted beagle dogs. Oral bioavailability (%F), defined as the fraction of oral ...
- Innocan Pharma Announces the Inauguration of Its Drug Development Lab at Biohouse in the Hadassah Medical Center in Jerusalemon January 17, 2022 at 1:00 pm
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has inaugurated its first and new drug research and development lab at ...
- Felix Biotechnology to Collaborate with AnimalBiome on a Novel Solution for Pet Diarrheaon January 14, 2022 at 10:16 am
Felix Biotechnology — a biotechnology company focused on developing first-in-class, accessible, antibacterial therapies to treat drug-resistant infections — today announced it signed a partnership ...
- Sniffer Dog for Drug Degradation Products - LIKAT Simplifies Molecular Labeling Process Using Deuteriumon January 13, 2022 at 9:56 pm
In the case of newly developed active ingredients it is important to know which degradation products (metabolites) are formed in the process, because these can be incompatible or even harmful. To ...
- Global Pet Insurance Market Size to Reach USD 14.52 Billion in 2028 | Reports And Dataon January 13, 2022 at 12:14 pm
Increasing pet adoption across the globe rising prevalence of various diseases and infections in dogs and cats& increasing pet care expenditure are key factors. NEW YORK, NY, UNITED STATES, / ...
via Bing News
